Cybin (HELP) Common Equity (2021 - 2025)
Cybin's (HELP) quarterly Common Equity came in at $273.9 million in Q4 2025, up 59.29% YoY from $172.0 million in Q4 2024, and up 97.08% on a QoQ basis from $139.0 million in Q3 2025.
Cybin (HELP) Common Equity (2021 - 2025) Analysis & Trends
Cybin (HELP) has 5 years of Common Equity data on file, last reported at $273.9 million in Q4 2025.
- Quarterly Common Equity rose 59.29% year-over-year to $273.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $273.9 million (up 59.29% YoY) and the FY2024 annual result came in at $216.6 million, changed N/A from the prior year.
- Common Equity improved to $273.9 million in Q4 2025, from $139.0 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $273.9 million in Q4 2025 to a low of $30.5 million in Q1 2023.
- A 5-year average of $113.0 million and a median of $79.0 million in 2021 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity plunged 41.29% — and 2024, when it jumped 417.97%.
- Tracing HELP's Common Equity over 5 years: stood at $70.7 million in 2021, then slumped by 41.29% to $41.5 million in 2022, then soared by 114.58% to $89.0 million in 2023, then soared by 93.14% to $172.0 million in 2024, then surged by 59.29% to $273.9 million in 2025.
- The last three Common Equity figures came in at $273.9 million (Q4 2025), $139.0 million (Q3 2025), and $151.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 273.93 Mn |
| Sep 30, 2025 | 139.00 Mn |
| Jun 30, 2025 | 151.76 Mn |
| Dec 31, 2024 | 171.98 Mn |
| Sep 30, 2024 | 186.94 Mn |
| Jun 30, 2024 | 204.60 Mn |
| Mar 31, 2024 | 216.64 Mn |
| Dec 31, 2023 | 89.04 Mn |
| Sep 30, 2023 | 36.09 Mn |
| Jun 30, 2023 | 50.67 Mn |
| Feb 28, 2023 | 30.46 Mn |
| Dec 31, 2022 | 41.49 Mn |
| Sep 30, 2022 | 49.25 Mn |
| Dec 31, 2021 | 70.68 Mn |
| Sep 30, 2021 | 78.96 Mn |
| Jun 30, 2021 | 62.05 Mn |
| Mar 31, 2021 | 68.04 Mn |